Processa Pharmaceuticals (PCSA) Deferred Taxes (2018 - 2021)

Processa Pharmaceuticals (PCSA) has reported Deferred Taxes for 4 consecutive years, with -$181752.0 the latest figure, recorded in Q4 2021.

• For the quarter ending Q4 2021, Deferred Taxes rose 74.57% year-over-year to -$181752.0; the trailing twelve-month figure through Dec 2021 stood at -$530611.0 (up 46.99% YoY), and the FY2021 full-year result was -$530611.0, up 46.99% from the prior year.
• Deferred Taxes declined to -$181752.0 in Q4 2021 per PCSA's latest filing, from -$122442.0 in the prior quarter.
• Across five years, Deferred Taxes topped out at -$70457.0 in Q3 2020 and bottomed at -$714598.0 in Q4 2020.
• Historically, Deferred Taxes has averaged -$189821.7 across 4 years, with a median of -$139210.0 in 2019.
• The sharpest annual moves came in 2020 and 2021: Deferred Taxes plunged 345.05% in 2020, then surged 74.57% in 2021.
• Over 4 years, Deferred Taxes stood at -$131469.0 in 2018, then retreated by 22.13% to -$160564.0 in 2019, then tumbled by 345.05% to -$714598.0 in 2020, then soared by 74.57% to -$181752.0 in 2021.
• According to Business Quant data, Deferred Taxes over the past three periods registered -$181752.0, -$122442.0, and -$137169.0 for Q4 2021, Q3 2021, and Q2 2021 respectively.